Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Y. K. Onno Teng"'
Autor:
Koos P. J. van Dam, Adriaan G. Volkers, Luuk Wieske, Eileen W. Stalman, Laura Y. L. Kummer, Zoé L. E. van Kempen, Joep Killestein, Sander W. Tas, Laura Boekel, Gerrit J. Wolbink, Anneke J. van der Kooi, Joost Raaphorst, R. Bart Takkenberg, Geert R. A. M. D’Haens, Phyllis I. Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. Post, Angela L. Bosma, Marc L. Hilhorst, Yosta Vegting, Frederike J. Bemelman, Alexandre E. Voskuyl, Bo Broens, Agner Parra Sanchez, Cécile A. C. M. van Els, Jelle de Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horváth, Jan J. G. M. Verschuuren, Annabel M. Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Renée C. F. Allaart, Y. K. Onno Teng, Pieter van Paassen, Matthias H. Busch, Papay B. P. Jallah, Esther Brusse, Pieter A. van Doorn, Adája E. Baars, Dirk Jan Hijnen, Corine R. G. Schreurs, W. Ludo van der Pol, H. Stephan Goedee, Maurice Steenhuis, Sofie Keijzer, Jim B. D. Keijser, Olvi Cristianawati, Anja ten Brinke, Niels J. M. Verstegen, S. Marieke van Ham, Theo Rispens, Taco W. Kuijpers, Mark Löwenberg, Filip Eftimov, on behalf of the T2B! Immunity against SARS-CoV-2 study group
Publikováno v:
BMC Infectious Diseases, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants (ISPs) may have impaired long-term humoral immune responses and increased disease activity after SARS-CoV-2 infection. We aimed to investigate long-
Externí odkaz:
https://doaj.org/article/8a6e2bdaa5404154a54ecf8fcb54843c
Autor:
Mieke van Schaik, Eline J. Arends, Darius Soonawala, Ellen van Ommen, Karina de Leeuw, Maarten Limper, Pieter van Paassen, Tom W. J. Huizinga, René E. M. Toes, Cees van Kooten, Joris I. Rotmans, Ton J. Rabelink, Y. K. Onno Teng
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background Belimumab, an anti-B-cell activating factor antibody, is approved for the treatment of auto-antibody positive systemic lupus erythematosus with a high degree of disease activity. Anti-CD20 B cell depletion with rituximab is used i
Externí odkaz:
https://doaj.org/article/40ea93bde1b948b18e6192b68708ecea
Autor:
Luuk Wieske, Laura Y. L. Kummer, Koos P. J. van Dam, Eileen W. Stalman, Anneke J. van der Kooi, Joost Raaphorst, Mark Löwenberg, R. Bart Takkenberg, Adriaan G. Volkers, Geert R. A. M. D’Haens, Sander W. Tas, Phyllis I. Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. Post, Angela L. Bosma, Marc L. Hilhorst, Yosta Vegting, Frederike J. Bemelman, Joep Killestein, Zoé L. E. van Kempen, Alexandre E. Voskuyl, Bo Broens, Agner Parra Sanchez, Gertjan Wolbink, Laura Boekel, Abraham Rutgers, Karina de Leeuw, Barbara Horváth, Jan J. G. M. Verschuuren, Annabel M. Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Cornelia F. Allaart, Y. K. Onno Teng, Pieter van Paassen, Matthias H. Busch, B. Papay Jallah, Esther Brusse, Pieter A. van Doorn, Adája E. Baars, Dirkjan Hijnen, Corine R. G. Schreurs, W. Ludo van der Pol, H. Stephan Goedee, Maurice Steenhuis, Theo Rispens, Anja ten Brinke, Niels J. M. Verstegen, Koos A. H. Zwinderman, S. Marieke van Ham, Taco W. Kuijpers, Filip Eftimov, on behalf of the T2B! immunity against SARS-CoV-2 study group
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-6 (2022)
Abstract Background Studies have suggested incremental short-term adverse events (AE) after repeated vaccination. In this report, we assessed occurrence and risk factors for short-term AEs following repeated SARS-CoV-2 vaccination in patients with va
Externí odkaz:
https://doaj.org/article/67db8621c3964b7a9443d09b66e09e5f
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Externí odkaz:
https://doaj.org/article/06c6ac88e1c4436ca18a72e5c00b393d
Autor:
Nadia M. T. Roodenrijs, Maria J. H. de Hair, Gill Wheater, Mohsen Elshahaly, Janneke Tekstra, Y. K. Onno Teng, Floris P. J. G. Lafeber, Ching Chang Hwang, Xinyu Liu, Eric H. Sasso, Jacob M. van Laar
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-9 (2018)
Abstract Background A multi-biomarker disease activity (MBDA) score has been validated as an objective measure of disease activity in rheumatoid arthritis (RA) and shown to track response to treatment with several disease-modifying anti-rheumatic dru
Externí odkaz:
https://doaj.org/article/b1fc4890e119437d8acbe3965b4311de
Autor:
Laura S. van Dam, Jelle M. Oskam, Sylvia W. A. Kamerling, Eline J. Arends, O. W. Bredewold, Magdalena A. Berkowska, Jacques J. M. van Dongen, Ton J. Rabelink, Cees van Kooten, Y. K. Onno Teng
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
BackgroundB-cell depletion with rituximab (RTX) is an effective treatment for anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) patients. Nevertheless, relapses are frequent after RTX, often preceded by B-cell repopulation sug
Externí odkaz:
https://doaj.org/article/88a01c1caada4b079f0609fa32b551e0
Autor:
Cees van Kooten, Y K Onno Teng, Willem Jan Bos, Obbo W Bredewold, Argho Ray, Jacqueline T Jonker, Hilde H F Remmelts, Ebru Dirikgil, Jolijn R van Leeuwen, Darius Soonawala, Bastiaan van Dam, Joris Rotmans, Ton Rabelink, Laura S van Dam
Publikováno v:
BMJ Open, Vol 12, Iss 9 (2022)
Introduction Both rituximab (RTX) and cyclophosphamide (CYC) are effectively used in combination with steroids as remission induction therapy for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Several studies ha
Externí odkaz:
https://doaj.org/article/93e10e71ff174e9784e45f43637e181b
Publikováno v:
Nature Reviews Rheumatology. 19:227-238
Autor:
Laura Boekel, Eileen W Stalman, Luuk Wieske, Femke Hooijberg, Koos P J van Dam, Yaëlle R Besten, Laura Y L Kummer, Maurice Steenhuis, Zoé L E van Kempen, Joep Killestein, Adriaan G Volkers, Sander W Tas, Anneke J van der Kooi, Joost Raaphorst, Mark Löwenberg, R Bart Takkenberg, Geert R A M D'Haens, Phyllis I Spuls, Marcel W Bekkenk, Annelie H Musters, Nicoline F Post, Angela L Bosma, Marc L Hilhorst, Yosta Vegting, Frederike J Bemelman, Alexandre E Voskuyl, Bo Broens, Agner Parra Sanchez, Cécile A C M van Els, Jelle de Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horváth, Jan J G M Verschuuren, Annabel M Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Cornelia F Allaart, Y K Onno Teng, Pieter van Paassen, Matthias H Busch, Papay B P Jallah, Esther Brusse, Pieter A van Doorn, Adája E Baars, Dirk Jan Hijnen, Corine R G Schreurs, W Ludo van der Pol, H Stephan Goedee, Erik H Vogelzang, Maureen Leeuw, Sadaf Atiqi, Ronald van Vollenhoven, Martijn Gerritsen, Irene E van der Horst-Bruinsma, Willem F Lems, Mike T Nurmohamed, Maarten Boers, Sofie Keijzer, Jim Keijser, Carolien van de Sandt, Arend Boogaard, Olvi Cristianawati, Anja ten Brinke, Niels J M Verstegen, Koos A H Zwinderman, S Marieke van Ham, Theo Rispens, Taco W Kuijpers, Gertjan Wolbink, Filip Eftimov, Rivka de Jongh, Lisan Kuijper, Mariel Duurland, Ruth Hagen, Jet van den Dijssel, Christine Kreher, Amelie Bos, Viriginia Palomares Cabeza, Veronique Konijn, George Elias, Juan Vallejo, Marrit van Gils, Tom Ashhurst, Sergey Nejentsev, Elham Mirfazeli
Publikováno v:
The Lancet Rheumatology, 4(6), e417-e429. Lancet Publishing Group
The Lancet. Rheumatology, 4, e417-e429
T2B! immunity against SARS-CoV-2 study group 2022, ' Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants : a substudy of two prospective cohort studies ', The Lancet Rheumatology, vol. 4, no. 6, pp. e417-e429 . https://doi.org/10.1016/S2665-9913(22)00102-3
The Lancet Rheumatology, 4(6), E417-E429. ELSEVIER
The Lancet. Rheumatology, 4, 6, pp. e417-e429
The Lancet. Rheumatology, 4(6), e417-e429. Elsevier Ltd
The Lancet Rheumatology, 4(6), e417-e429. Elsevier
The Lancet. Rheumatology, 4, e417-e429
T2B! immunity against SARS-CoV-2 study group 2022, ' Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants : a substudy of two prospective cohort studies ', The Lancet Rheumatology, vol. 4, no. 6, pp. e417-e429 . https://doi.org/10.1016/S2665-9913(22)00102-3
The Lancet Rheumatology, 4(6), E417-E429. ELSEVIER
The Lancet. Rheumatology, 4, 6, pp. e417-e429
The Lancet. Rheumatology, 4(6), e417-e429. Elsevier Ltd
The Lancet Rheumatology, 4(6), e417-e429. Elsevier
Contains fulltext : 251784.pdf (Publisher’s version ) (Closed access) BACKGROUND: Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough infections in vaccinated patients with immune-mediated inflammatory diseases treated with imm
Autor:
Cristina Arriens, Y. K. Onno Teng, Ellen M. Ginzler, Samir V. Parikh, Anca D. Askanase, Amit Saxena, Keisha Gibson, Dawn J. Caster, Tatsuya Atsumi, Laura Lisk, Simrat Randhawa, Rashieda Gluck, Neil Solomons, Robert B. Huizinga
Publikováno v:
Arthritis Care & Research. WILEY
Arthritis Care & Research
Arthritis Care & Research
Objective: This integrated analysis evaluates the efficacy and safety of voclosporin, a novel calcineurin inhibitor, at 23.7 mg twice daily in combination with mycophenolate mofetil (MMF) and oral glucocorticoids in lupus nephritis (LN) using pooled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89c2b117499236e83beda77190e71886
https://hdl.handle.net/1887/3566472
https://hdl.handle.net/1887/3566472